Prostate Cancer Screenings on the Decline with Concerns Surrounding COVID-19: What Men Should Know
Feb. 22, 2021
FacebookTwitterEmail
(BPT) - In the early part of the COVID-19 pandemic, many areas of the country banned nonessential medical procedures in an effort to slow the spread of the disease. As a result, many physicians saw fewer patients for routine medical care, such as physical exams and screenings. A recent survey by The Physicians Foundation polled 3,513 physicians and found 41% saw volume decreases of 26% or more in their practices.
The impact on cancer screenings was even more profound. For example, screenings for prostate cancer one of the most commonly diagnosed cancers in men in the United States dropped by 56% by the peak of the pandemic in April according to a recent study published in
Theralase Launches Fourth Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.
Theralase Technologies Inc.: Theralase Launches Fourth Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study
Theralase® Technologies Inc. (
TSXV:TLT) (
OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (
PDC ) and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that Carolina Urologic Research Center ( C
URC ) has received site Institutional Review Board (
IRB ) approval to commence a Pivotal Phase II Non-Muscle Invasive Bladder Cancer (
NMIBC ) Clinical Study to enroll and treat patients with Bacillus Calmette Guerin(
Study II ).
Facing Prostate Cancer with the Help of Precision Medicine sfgate.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sfgate.com Daily Mail and Mail on Sunday newspapers.
FDA approves Myovant’s oral pill Orgovyx for prostate cancer
This is a new option for advanced prostate cancer patients in the US
The US Food and Drug Administration (FDA) has approved Myovant’s once-daily pill Orgovyx for prostate cancer.
Orgovyx (relugolix), which will become available for advanced prostate cancer patients in the US, offers a new option that enables at-home administration.
This is a particularly attractive option for patients looking to avoid travelling for in-person injections, especially in light of the ongoing COVID-19 pandemic.
“The COVID-19 pandemic has heightened the importance of oral treatments as men with prostate cancer continue to experience difficulties and risks travelling to receive injections,” said Neal Shore, medical director of the Carolina Urologic Research Center and HERO programme steering committee member.